Report finds growing number of drug prices rising without merit
Half of the ten fastest-rising drug prices without any evidence of improved value last year, according to the latest report from ICER. This is the highest percentage of unsupported prescription drug prices since ICER began this report in 2019. The increased prices rose far faster than inflation for the rest of the economy. Just the increase in these five drugs cost US healthcare $815 million just last year. The five drugs are Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz. ICER’s report is based on net drug prices that include rebate reductions.
| Drug | 2022-2023 net price change | Resulting extra drug spending |
| Biktarvy | 3.8% | $359 million |
| Darzalex | 3.7% | $190 million |
| Entresto | 3.6% | $108 million |
| Cabometyx | 5.9% | $86 million |
| Xeljanz | 6.7% | $72 million |